Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, has scheduled its third quarter 2024 financial results release for Thursday, November 7, 2024, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial and business results. Interested parties can register for the conference call through a provided link, which will supply a dial-in number and unique PIN. A webcast replay will be available on the company's website for thirty days following the call.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX), un'azienda farmaceutica specializzata in fase commerciale, ha programmato il rilascio dei risultati finanziari del terzo trimestre 2024 per giovedì 7 novembre 2024, prima dell'apertura dei mercati statunitensi. L'azienda ospiterà una conference call e una trasmissione in diretta alle 8:30 ora orientale per discutere i risultati finanziari e aziendali. Le parti interessate possono registrarsi per la conference call tramite un link fornito, che fornirà un numero di accesso e un PIN unico. Una registrazione della trasmissione sarà disponibile sul sito web dell'azienda per trenta giorni dopo la chiamata.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX), una compañía farmacéutica especializada en etapa comercial, ha programado la publicación de sus resultados financieros del tercer trimestre de 2024 para el jueves 7 de noviembre de 2024, antes de la apertura de los mercados en EE.UU. La empresa llevará a cabo una conferencia telefónica y una transmisión en línea a las 8:30 a.m. hora del Este para discutir los resultados financieros y empresariales. Las partes interesadas pueden registrarse para la conferencia telefónica a través de un enlace proporcionado, que suministrará un número de marcado y un PIN único. Una repetición de la transmisión estará disponible en el sitio web de la empresa durante treinta días después de la llamada.
펜엑 제약(NASDAQ: FENC; TSX: FRX)는 상업 단계의 전문 제약 회사로, 2024년 3분기 재무 결과 발표를 2024년 11월 7일 목요일, 미국 시장 개장 전에 예정하고 있습니다. 회사는 동부 표준시 기준 오전 8시 30분에 재무 및 비즈니스 결과에 대해 논의하기 위해 컨퍼런스 콜과 웹캐스트를 진행할 것입니다. 관심 있는 당사자들은 제공된 링크를 통해 컨퍼런스 콜에 등록할 수 있으며, 이 링크는 전화 접속 번호와 고유 PIN을 제공합니다. 웹캐스트 재생은 통화 후 30일 동안 회사 웹사이트에서 이용할 수 있습니다.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX), une entreprise pharmaceutique spécialisée en phase commerciale, a prévu la publication de ses résultats financiers du troisième trimestre 2024 pour le jeudi 7 novembre 2024, avant l'ouverture des marchés américains. L'entreprise organisera une conférence téléphonique et un webinaire à 8h30, heure de l'Est, pour discuter des résultats financiers et commerciaux. Les parties intéressées peuvent s'inscrire à la conférence téléphonique via un lien fourni, qui fournira un numéro de connexion et un code PIN unique. Une rediffusion du webinaire sera disponible sur le site Web de l'entreprise pendant trente jours après l'appel.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX), ein spezialisiertes pharmazeutisches Unternehmen in der kommerziellen Phase, hat die Veröffentlichung seiner Finanzergebnisse für das dritte Quartal 2024 für Donnerstag, den 7. November 2024, vor der Eröffnung der US-Märkte geplant. Das Unternehmen wird um 8:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast veranstalten, um die finanziellen und geschäftlichen Ergebnisse zu erörtern. Interessierte Parteien können sich über einen bereitgestellten Link für die Telefonkonferenz registrieren, der eine Durchwahl und eine eindeutige PIN bereitstellt. Eine Wiederholung des Webcasts wird für dreißig Tage nach dem Anruf auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.
Conference Call & Webcast Detail:
| Date: | Thursday, November 7, 2024 |
| Time: | 8:30 a.m. Eastern Time |
| Link: | https://edge.media-server.com/mmc/p/e6my278s |
To access the conference call, please register using https://edge.media-server.com/mmc/p/e6my278s. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
FAQ
When will Fennec Pharmaceuticals (FENC) release Q3 2024 earnings?
What time is Fennec Pharmaceuticals (FENC) Q3 2024 earnings call?
How can I access Fennec Pharmaceuticals (FENC) Q3 2024 earnings call?
